This Collaboratory application focuses on the best understood reservoir for HIV-1, the latent reservoir in resting CD4+ T cells. Our goal is to find small molecule approaches for targeting this reservoir. However, HlV-1 may also persist in other reservoirs in patients on H/ ART. Therefore a comprehensive approach to HIV-1 eradication requires the identification of all stable reservoirs and the development of strategies to eliminate each one. To this end, our laboratory has been analyzing the trace levels of residual viremia (RV) that can be detected using specialized assays in patients on HAART who have """"""""undetectable"""""""" viral loads by standard clinical assays. Because ofthe short half-life of free virus in the plasma, the presence of RV in patients on long term HAART indicates the ongoing production of virus in the presence of effective drugs. Thus, the analysis of RV provides a unique window into the state of virologic suppression and the reservoirs that stand in the way of eradication. Through sequence analysis of the trace levels of RV present in patients on HAART, our group and others have provided evidence that at least some fraction of the RV is derived from a source distinct from the latent reservoir in resting CD4+ T cells. The goals of the this project are to carry out exhaustive longitudinal sampling ofthe RV and the latent reservoir in unique patient populations and to compare the sequences from these two sources in order to verify the existence of additional reservoirs. Parallel studies will be carried out in SIV-infected macaques on HAART in a effort to find the source of the RV. Definitave demonstration of the existence of additional reservoirs contributing to RV will may require the development of alternative therapeutic approaches in addition to those targeting the latent reservoir in resting CD4+ T cells. Assessing the response of alternative reservoirs to strategies targeting the latent reservoir in initial clinical trials may provide critical information about the need for additional approaches to achieve eradication.
Curing HIV infection requires finding all of the reservoirs in the body where the virus can persist in patients on antiretroviral therapy. One reservoir has been identified, but there may be more. This application seeks to determine whether additional reservoirs exist. If so, novel strategies must be designed to eliminate them.
|Davis, Zachary B; Cogswell, Andrew; Scott, Hamish et al. (2016) A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog 12:e1005421|
|Imaz, Arkaitz; Martinez-Picado, Javier; NiubÃ³, Jordi et al. (2016) HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. J Infect Dis 214:1512-1519|
|Honeycutt, Jenna B; Wahl, Angela; Baker, Caroline et al. (2016) Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest 126:1353-66|
|Tokarev, Andrey; Stoneham, Charlotte; Lewinski, Mary K et al. (2016) Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1. J Virol 90:2486-502|
|Victor Garcia, J (2016) Humanized mice for HIV and AIDS research. Curr Opin Virol 19:56-64|
|Smith, Davey M; Nakazawa, Masato; Freeman, Michael L et al. (2016) Asymptomatic CMV Replication During Early Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower CD4/CD8 Ratio During HIV Treatment. Clin Infect Dis 63:1517-1524|
|Gianella, Sara; Anderson, Christy M; Var, Susanna R et al. (2016) Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. J Virol 90:3944-52|
|Garcia, J Victor (2016) In vivo platforms for analysis of HIV persistence and eradication. J Clin Invest 126:424-31|
|Lee, Sook-Kyung; Zhou, Shuntai; Baldoni, Pedro L et al. (2016) Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID In A Viral Outgrowth Assay. J Acquir Immune Defic Syndr :|
|Wagner, Gabriel A; Chaillon, Antoine; Liu, Siqi et al. (2016) HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS 30:2591-2597|
Showing the most recent 10 out of 187 publications